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Receptors that inhibit or activate NK cells can 
also be expressed on T cells, where they modu-
late TCR–CD3 complex–dependent responses 
(1–4). Among these receptors is NKG2D, which 
interacts with ligands that are absent from most 
normal  cells  but  can  be  transcriptionally  in-
duced by generic mechanisms of cellular stress 
and chromatin remodeling (5–9). In humans, 
NKG2D ligands include the MHC class I–
  related chain A (MICA), which is frequently as-
sociated with epithelial tumors, is induced by 
microbial infections, and is expressed in certain 
autoimmune  disease  target  tissues  (8,  10–14). 
Upon ligand engagement, NKG2D conveys di-
rectly activating or costimulatory signals via the 
paired DAP10 adaptor protein (4, 13, 15, 16). 
NKG2D may thus promote cancer and infec-
tious disease immunity, but worsen autoimmune 
disease progression. Consistent with its role in 
effector responses, NKG2D is present on virtu-
ally all NK cells and CD8 T cells (6).
However, NKG2D also costimulates prolif-
erative expansions of normally rare NKG2D+ 
CD4+ T cells that have negative regulatory 
functions and may serve to dampen chronic im-
mune activation resulting from persistent MICA 
expression (17). Small populations of CD4 T 
cells with activation-independent, constitutive, 
NKG2D expression occur in normal peripheral 
blood (6, 17–19). They appear biased toward 
an IL-10– and TGF-–dominated cytokine 
profile (17). Upon NKG2D costimulation, the 
NKG2D+CD4+ T cells also produce Fas li-
gand (FasL), causing growth arrest of bystander 
T cells in vitro, but are themselves resistant to 
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The NKG2D receptor stimulates natural killer cell and T cell responses upon engagement of 
ligands associated with malignancies and certain autoimmune diseases. However, conditions 
of persistent NKG2D ligand expression can lead to immunosuppression. In cancer patients, 
tumor expression and shedding of the MHC class I–related chain A (MICA) ligand of NKG2D 
drives proliferative expansions of NKG2D+CD4+ T cells that produce interleukin-10 (IL-10) 
and transforming growth factor-, as well as Fas ligand, which inhibits bystander T cell 
proliferation in vitro. Here, we show that increased frequencies of functionally equivalent 
NKG2D+CD4+ T cells are inversely correlated with disease activity in juvenile-onset systemic 
lupus erythematosus (SLE), suggesting that these T cells may have regulatory effects. The 
NKG2D+CD4+ T cells correspond to a normally occurring small CD4 T cell subset that is 
autoreactive, primed to produce IL-10, and clearly distinct from proinflammatory and 
cytolytic CD4 T cells with cytokine-induced NKG2D expression that occur in rheumatoid 
arthritis and Crohn’s disease. As classical regulatory T cell functions are typically impaired 
in SLE, it may be clinically significant that the immunosuppressive NKG2D+CD4+ T cells 
appear functionally uncompromised in this disease.
© 2009 Dai et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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these T cells (but not of NKG2DCD4+ T cells) in the presence 
of autologous PBMCs depleted of CD25+ T reg cells to unmask 
T cell reactivity (Fig. 1, A and B) (23). This response was solely 
dependent on B cells and MHC class II, as separately shown by 
CD19+ lymphocyte depletion and B cell reconstitution, and by 
anti–MHC class II antibody blocking. T cell and monocyte de-
pletions had no effect (Fig. 1 A). The costimulatory capacity of 
the ex vivo–purified B cells was caused by the expression of the 
UL16-binding protein (ULBP) 2 and 3 ligands of NKG2D (Fig. 
1 A) (24). The observed autoreactivity of the NKG2D+CD4+ T 
cells was confirmed with 32 T cell clones established from three 
unrelated  donors,  which  incorporated  [3H]thymidine  in  the 
presence of autologous, but not allogeneic, B cells and were re-
stricted by HLA-DR (Fig. 1 C).
Most  normal  peripheral  blood  NKG2D+CD4+  T  cells 
lack conventional markers of antigen exposure, an unex-
pected phenotype of an autoreactive T cell population that 
may frequently encounter self (17). However, CFSE dilution 
experiments with ex vivo–sorted, phenotypically naive CD4
5ROCD62L+CD28+CD27+NKG2D+CD4+ bulk responder 
T cells, and analysis of T cell clones established from single-
cell sorted naive NKG2D+CD4+ T cells, confirmed the oc-
currence of autoreactive and MHC class II–restricted T cell 
specificities within the naive NKG2D+CD4+ T cell pool 
(Fig. 2, A and B).
These results were complemented by evidence arguing 
against a primary role of the NKG2D+CD4+ T cells in host 
defense, as no memory responses by these T cells, isolated 
from CMV-seropositive and tuberculin skin test–positive in-
dividuals, were discernible against a panel of “recall” anti-
gens, including CMV pp65, tetanus toxoid, Mycobacterium 
tuberculosis–purified protein derivative, and Candida albicans 
(Fig. 3 A). In contrast, recall responses against all of these an-
tigens were readily detected with memory NKG2DCD4+ 
T cells (Fig. 3, D–G), as well as with NKG2D+CD4+ T cells 
coexpressing  CD8,  which  comprise  significant  propor-
tions (20–80%; not depicted) of NKG2D+CD4+ T cells if 
these are purified without taking CD8 into account (Fig. 3, 
B and C). These results are consistent with the fact that dou-
ble-positive CD8+CD4+NKG2D+ T cells are fully differ-
entiated  CD28  effector  memory  T  cells  enriched  for 
antimicrobial specificities, and suggest that the previously re-
corded CMV-driven expansions of NKG2D+CD4+ T cells 
may have been limited to proliferation of nonexcluded dou-
ble-positive T cells (22, 25).
Normal peripheral blood NKG2D+CD4+ T cells are primed  
to produce IL-10
Based on ELISA, bulk cultures of normally occurring NKG2D+ 
CD4+ T cells are biased toward an IL-10– and TGF-–dom-
inated cytokine profile (17). However, this trait has not been 
evaluated at the single-cell level or associated with matura-
tional T cell phenotypes. Moreover, the proinflammatory and 
cytolytic potential of these T cells has not been fully assessed. 
Using polychromatic flow cytometry, we simultaneously de-
termined cytokine production and CD45RO/CCR7-defined 
Fas-mediated homeostatic regulation (17). Hence, in tissue 
environments providing stimulation of TCR and NKG2D, 
the NKG2D+CD4+ T cells may expand in numbers relative 
to other T cells, causing imbalances in the lymphocyte pool 
and imposing an immunosuppressive cytokine milieu. This 
model is supported by proliferative expansions, driven by tu-
mor-associated and shed soluble MICA (sMICA), of IL-10, 
TGF-, and FasL-producing NKG2D+CD4+ T cells in late-
stage cancer patients (17). Because these T cells are stimulated 
by cancer cells of diverse tissue origins, it seems probable that 
they recognize normal self-antigens as opposed to malignancy-
associated antigens.
By inference, persistent expression of MICA in tissues af-
fected by autoimmune pathology might also result in expan-
sions of the suppressive NKG2D+CD4+ T cells. In this 
scenario, the NKG2D+CD4+ T cells would be expected to 
ameliorate disease severity, thus resembling regulatory T (T reg) 
cells (20, 21). This conceptual view of regulatory NKG2D+ 
CD4+ T cells is complicated by occurrences of effector 
NKG2D+CD4+  T  cells  from  which  they  must  be  distin-
guished. IFN- and TNF- producing cytotoxic NKG2D+ 
CD4+ T cells occur in rheumatoid arthritis (RA) patients, 
and frequencies of perforin-positive NKG2D+CD4+ T cells 
correlate with the severity of Crohn’s disease (11, 18). Addi-
tional complexity is suggested by observations that cytotoxic 
NKG2D+CD4+ T cell expansions may be driven by CMV 
(22). These discrepancies could be explained by the existence 
of developmentally distinct NKG2D+CD4+ T cell popula-
tions, including the normally occurring subset mainly charac-
terized by production of IL-10 and TGF-, and an effector 
subset with NKG2D expression that is cytokine induced 
(11, 18). Alternatively, normally occurring NKG2D+CD4+ 
T cells could be functionally heterogeneous.
In this study, we show that normally occurring NKG2D+ 
CD4+  T  cells  in  healthy  individuals  are  autoreactive  and 
primed to produce IL-10, but lack proinflammatory cytokine 
and cytolytic signatures and play no discernible role in anti-
microbial recall responses. Large expansions of these T cells 
in patients with juvenile-onset systemic lupus erythematosus 
(SLE) are inversely correlated with activity of disease, thus 
suggesting that they participate in regulation of effector re-
sponses that provoke autoimmunity.
RESULTS
Normal peripheral blood NKG2D+CD4+ T cells  
are autoreactive
Functional attributes of normal peripheral blood NKG2D+ 
CD4+ T cells, which occur at frequencies of 0.5–3%, are in-
sufficiently defined (17). We therefore examined their autoreac-
tivity, cytokine signature, and cytolytic capacity. We have 
previously shown that NKG2D+CD4+ T cell clones derived 
from an ovarian cancer patient produce IL-10 and TGF- upon 
recognition of MHC class II complexes on autologous tumor 
and B lymphoblastoid cells (unpublished data) (17). Autoreactiv-
ity of normal peripheral blood NKG2D+CD4+ T cells was es-
tablished in CFSE dilution assays, demonstrating proliferation of JEM VOL. 206, April 13, 2009 
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naive and memory phenotypes of peripheral blood NKG2D+ 
CD4+ T cells after short-term polyclonal stimulation. Con-
sistent with the previous data, the T cells produced IL-10, 
TGF-, and only a small amount of IFN-, and were nega-
tive for IL-2 and IL-4. Proinflammatory TNF- and IL-17 
cytokines were not produced (Fig. 4, A–D, and not depicted). 
Among the positive cytokines, IL-10 was most frequently 
detected and associated with all T cell differentiation stages 
representing 48.9 ± 13.8%, 65.7 ± 12.6%, and 51.5 ± 10.2% 
(mean  percentage  ±  SD  for  10  donors)  of  naive,  central 
memory, and effector memory NKG2D+CD4+ T cells, re-
spectively (Fig. 4 B). TGF- induction was recorded with 
central memory (39.8 ± 12.2%) and effector memory (43.7 ± 
9%), but not naive NKG2D+CD4+, T cells by surface stain-
ing for the latency-associated peptide (LAP), which nonco-
valently associates with mature TGF- homodimers (Fig. 4 C) 
(26). These results were independently confirmed by staining 
for intracellular LAP-TGF- (unpublished data). Because of 
different T cell stimulation time periods required for optimal 
IL-10 and TGF- induction, these cytokines could not be 
simultaneously  tested.  Minimal  IFN-  responses  were  re-
corded with small populations (13.8 ± 8.6%) of IL-10 pro-
ducing effector memory NKG2D+CD4+ T cells (Fig. 4 D). 
Figure 1.  Autoreactivity of normal peripheral blood NKG2D+CD4+ 
T cells. (A) NKG2D+CD4+ T cells proliferate in the presence of CD25+ cell–
depleted autologous PBMCs. CD3+CD4+CD8NKG2D+ T cells FACSAria-
sorted from magnetic bead–enriched CD4+ T cells to ≥99% purity were 
labeled with CFSE and cultured with irradiated autologous total or CD25 
stimulator PBMCs, or subpopulations thereof, as indicated. CD25+ lym-
phocytes were depleted to enhance T cell proliferation (23). Autoreactive 
NKG2D+CD4+ T cell stimulation is solely dependent on B cells as shown 
separately by B cell depletion and reconstitution. T cell and monocyte 
depletions have no effect. Blocking antibodies are specific for MHC class II 
(mAb TU39), and ULBP2 or ULBP3 (mAbs 6F6 and 4F9). The CFSE profiles 
shown represent gated NKG2D+CD4+ T cells. (B) Purified NKG2DCD4+ T 
cells fail to proliferate in the presence of CD25+ cell–depleted autologous 
PBMCs. Treatment of NKG2DCD4+ T cells with PHA is shown as positive 
control. CFSE profiles represent gated NKG2DCD4+ T cells. Data shown in 
A and B are representative of results obtained in duplicate experiments 
with PBMCs from five independent donors. (C) Thymidine incorporation 
by NKG2D+CD4+ T cell clones in the presence of autologous, but not al-
logeneic, B cells is inhibited by anti-MHC class II (mAb TU39) and -HLA-
DR (mAb L243). Clones 1–3 were derived from 3 donors and are 
representative of a total of 32 clones. Error bars indicate deviations 
among triplicate wells. Data shown are representative of three experi-
ments per clone.
Figure 2.  Autoreactivity of phenotypically naive NKG2D+CD4+ T 
cells. (A) CD3+CD4+CD8CD45RA+CD45ROCD62L+CCR7+CD28+CD27+NKG
2D+ T cells FACSAria sorted from magnetic bead–enriched CD4+ T cells to 
>99% purity dilute CFSE in the presence of autologous, but not allogeneic, 
B cells. Proliferation is inhibited by anti-MHC class II mAb TU39. CFSE pro-
files shown represent gated NKG2D+CD4+ T cells and are representative of 
data obtained in duplicate experiments with PBMCs from five independent 
donors. (B) NKG2D+CD4+ T cell clones derived from single-cell sorted naive 
NKG2D+CD4+ T cells incorporate [3H]thymidine in the presence of autolo-
gous, but not allogeneic B cells. Proliferative responses are inhibited by mAb 
TU39. Clones 1–3 are representative of a total of 60 clones established from 
3 donors. Error bars indicate deviations among triplicate wells. Data shown 
are representative of three experiments per clone.796 IMMUNOSUPPRESSIVE NKG2D+CD4+ T CELLS | Dai et al.
cells as a distinct T cell subset that is autoreactive, has no pro-
inflammatory and cytolytic features, and is primed to produce 
IL-10. These T cells are unusual because they are endowed 
with an isolated and immediate IL-10 response at a pheno-
typically naive stage. This quasi innate status is unaligned with 
the peripheral polarization of conventional T cells and may 
involve genetic imprinting of the IL-10 locus independent of 
antigenic stimulation (27, 28).
Frequencies of NKG2D+CD4+ T cells are negatively 
correlated with disease activity in juvenile-onset SLE
Our observations in advanced tumor settings led us to test 
whether the NKG2D+CD4+ T cells resemble conventional 
T reg cells, with similarly opposed negative and protective 
effects in tumor immunity and autoimmune diseases, respec-
tively. We examined NKG2D+CD4+ T cell frequencies in 
proportion to all CD4 T cells in juvenile-onset SLE. In the 
course of this disease, patients undergo spontaneous flares and 
remissions, thus enabling comparisons of fluctuating disease 
activity data points, which were graded according to the SLE 
disease activity index (SLEDAI) (29). We scored proportional 
increases of NKG2D+CD4+ T cells in 13 active (SLEDAI ≥ 5) 
and 14 inactive (SLEDAI < 5) SLE patient peripheral blood 
samples in comparison to 14 age-matched controls (3 repre-
sentative examples for each category are shown in Fig. 6 A). 
The overall data point distribution indicated a significant (P = 
0.002) inverse correlation (R = –0.5) between NKG2D+CD4+ 
T cell frequencies and SLEDAI scores (Fig. 6 B). Compari-
sons of mean T cell frequencies in active and inactive SLE 
samples and controls revealed highly significant associations 
(P < 0.0001) with the disease in general, and confirmed the 
inverse correlation with disease severity in particular (Fig. 6 C). 
By flow cytometry testing for perforin, granzymes A and B, 
and activation-induced surface mobilization of the CD107a 
degranulation marker, the peripheral blood NKG2D+CD4+ 
T cells displayed no sign of cytolytic capacity (Fig. 4 E and 
not depicted). Among these results, the isolated (IL-10 only) 
and rapid (within 6 h of polyclonal stimulation) cytokine re-
sponse by the tentatively naive CD45ROCCR7+NKG2D+ 
CD4+ T cells was highly unusual. However, we made the 
same observation with CD45ROCCR7+NKG2D+CD4+ 
T cells from cord blood and with bona fide naive (CD45RA+ 
CD62L+CD28+CD27+CD11a) NKG2D+CD4+ T cells from 
peripheral blood and cord blood (Fig. 4 F and not depicted).
The cytokine profiles of NKG2D+CD4+ T cells were 
confirmed by clonal analysis of naive and memory subset T 
cells after FACS sorting into single wells and expansion under 
nonpolarizing conditions. All clones that originated from 
phenotypically naive NKG2D+CD4+ T cells produced IL-10 
only, whereas most memory subset-derived clones were also 
positive for intracellular and surface LAP-TGF- (Fig. 5 A, 
left and middle, and not depicted). Consistent with the minor 
IFN- responses recorded with some peripheral blood effec-
tor memory NKG2D+CD4+ T cells (Fig. 4 D, left), 3 out of 
20 IL-10+ effector memory subset-derived clones included 
small populations of IFN-–producing cells (Fig. 5 A, right). 
All clones were negative for TNF- and IL-17, lacked cyto-
toxic proteins, and redirected lysis activity against P815 cells 
(unpublished data). These and the autoreactive T cell clones 
tested above (see first paragraph of Results) were further used 
for confirmation of FasL production, which is the principal 
mediator of NKG2D+CD4+ T cell regulatory functions, at 
least in vitro (Fig. 5 B and not depicted) (17). Altogether, 
these results establish normally occurring NKG2D+CD4+ T 
Figure 3.  Absence of recall responses by NKG2D+CD4+ T cells. (A) By CFSE dilution, purified memory NKG2D+CD8CD4+ T cells are unresponsive to stimu-
lation by autologous monocytes pulsed with CMV pp65, tetanus toxoid (TT), M. tuberculosis–purified protein derivative (Mt PPD), and C. albicans (Ca) antigen 
cocktail. (B) Proliferation of NKG2D+CD4+ T cells nondepleted for CD8 coexpressing T cells. (C) CFSE diluting T cells seen in B (profile left of vertical line) are double-
positive CD8+CD4+ NKG2D+ T cells. (D−G) Proliferation of donor-matched purified memory NKG2DCD4+ T cells upon stimulation by monocytes pulsed with 
the individual recall antigens. Data shown are representative of results obtained in duplicate experiments with PBMC from five donors.JEM VOL. 206, April 13, 2009 
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This relationship was further supported by data point pairs 
from five patients with serial samples obtained during periods 
of flare and subsequent remission of disease, which illustrated 
the link between changes in disease activity and NKG2D+ 
CD4+ T cell frequencies (Fig. 6 D). Notably, these fluctuating 
proportions corresponded to changes in absolute NKG2D+ 
CD4+ T cell numbers, with means of 38.7 ± 21.5 and 287.1 ± 
130.6 cells per mm3 in the five serial flare and remission   
juvenile-onset SLE patient peripheral blood sample pairs, re-
spectively. There was no statistically significant (P = 0.12) as-
sociation between NKG2D+CD4+ T cell frequencies and the 
presence or absence of immunosuppressive therapy (Table I). 
Altogether, these results suggested that the NKG2D+CD4+ T 
cells may be associated with regulatory effects.
Functional correspondence between juvenile-onset SLE 
patient and normally occurring NKG2D+CD4+ T cells
Immune regulation by NKG2D+CD4+ T cells is likely mul-
tifactorial, involving IL-10 and TGF- cytokine and FasL 
production in response to self-antigen recognition and NKG2D 
costimulation, and may be perpetuated by their resistance to 
Fas-mediated homeostatic regulation. We scrutinized the 
functional attributes of NKG2D+CD4+ T cells in juvenile-
onset SLE, taking into account that they may represent mixed 
populations that also include the proinflammatory and cyto-
lytic CD4 T cells with cytokine-induced NKG2D expression 
described in RA and Crohn’s disease (11, 18). Autoreactivity 
was confirmed in CFSE dilution experiments using autolo-
gous stimulator B cells (Fig. 7 A, left histogram). As determined 
by polychromatic flow cytometry, ex vivo SLE NKG2D+CD4+ 
T cells from all 13 active and 14 inactive disease samples dis-
played the IL-10 and TGF- cytokine signature, produced 
minimal IFN-, and were negative for TNF-, IL-17, and 
cytolytic markers (Fig. 7, A and B, and not depicted). Consis-
tent with antigen-driven activation, most SLE NKG2D+CD4+ 
T cells expressed memory phenotypes, whereas, as noted for 
normal adults, age-matched control T cells were largely naive 
(Table II). The memory and naive NKG2D+CD4+ T cell 
subset segregation was similar among samples from active and 
inactive disease patients. The proportions of IL-10–produc-
ing cells among the patient-derived NKG2D+CD4+ T cells 
(72.6 ± 9.2%) were larger than those among age-matched 
controls (56 ± 11.7%), but were comparable between the ac-
tive (72.2 ± 9.1%) and inactive (73 ± 9.2%) disease sample 
cohorts. Similar T cell proportions and numerical relation-
ships were scored by analysis of all patient and control samples 
Figure 4.  IL-10 and TGF- cytokine signature of peripheral blood 
and cord blood NKG2D+CD4+ T cells after short-term stimulation 
with PMA and ionomycin. (A) Polychromatic flow cytometry gating tree 
for naive (N; CD45ROCCR7+), central memory (CM; CD45RO+CCR7+), and 
effector memory (EM; CD45ROCCR7) NKG2D+CD8CD4+CD3+ T cells. 
Numbers in quadrants and square gate specify T cell frequencies (in per-
cent). All histograms shown in B–D were generated based on this gating 
tree. (B) Staining for intracellular IL-10 of naive (N) and central (CM) and 
effector (EM) memory NKG2D+CD4+ T cells. (C) Staining of surface LAP-
TGF-1 on memory (CM and EM), but not naive (N), NKG2D+CD4+ T cells. 
(D) Minimal detection of intracellular IFN- and absence of TNF- and IL-
17 in effector memory (EM) and total NKG2D+CD4+ T cell populations, 
respectively. (E) Lack of intracellular staining of naive and memory (CM 
and EM) NKG2D+CD4+ T cells for perforin and granzymes A and B using 
an antibody cocktail. Gating was as shown in A. Histogram at right shows 
positive control staining of CD4 T cells with IL-15–induced NKG2D ex-
pression (11). (F) Gating tree and intracellular IL-10 staining of naive 
(CD45ROCCR7+) NKG2D+CD4+ T cells among CBMCs. Numbers specify T 
cell frequencies (in percent). Numbers above horizontal bars in histograms 
B−D and F indicate the percentage of positive cells. Histograms shown in 
red and black are from stimulated and unstimulated T cells, respectively. 
Data shown are representative of results obtained in duplicate experi-
ments with samples from 10 donors.
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for intracellular and surface LAP–TGF- (unpublished data). 
IFN- responses were limited to 9.9 ± 9% and 11.4 ± 7.8% 
effector memory NKG2D+CD4+ T cells from patients with 
active and inactive disease, respectively (Fig. 7 B).
Functional competence of NKG2D+CD4+ T cells in juvenile-
onset SLE
It is well known that T cell signaling and functions are aber-
rant in SLE, and some studies suggest that CD25+ T reg cells 
are functionally compromised (30, 31). It was therefore nec-
essary to scrutinize the inverse correlation between disease 
activity and NKG2D+CD4+ T cell numbers by examining T 
cell functional competence in the context of population size. 
As determined by ELISA, purified memory NKG2D+CD4+ 
T cells from active and inactive disease patients, as well as 
age-matched controls, secreted similar amounts of IL-10, 
TGF-,  and  FasL  after  stimulation  with  solid-phase  anti-
CD3 and sMICA (Fig. 8 A). Corresponding results were ob-
tained by analysis of T cell clones (unpublished data). As 
previously shown with NKG2D+CD4+ T cells from tumor 
patients and normal controls (17), FasL produced by those T 
cells from juvenile-onset SLE patients representing both ends 
of the disease spectrum effectively induced Fas-mediated 
growth arrest of NKG2DCD4+ T cells from normal con-
trols (Fig. 8 B). NKG2D+CD4+ T cells from active and in-
active SLE patients were also equally potent in inducing 
Fas-mediated inhibition of proliferation of patient-derived 
NKG2DCD4+ T cells (Fig. 8 C).
Together, these results indicate that most, if not all, 
NKG2D+CD4+ T cells in juvenile-onset SLE are progeny of 
the normally occurring NKG2D+CD4+ T cell subset. The 
functional disposition of these T cells appears relatively invari-
ant and independent of disease activity, with the caveat that 
our in vitro analysis cannot account for factors that may mod-
ulate T cell functions in physiological environments. It re-
mains unclear which of the NKG2D+CD4+ T cell functions, 
individually or in combination, may be related to ameliorat-
ing disease. However, IL-10 and FasL, determined in SLE pa-
tient plasma samples by ELISA, were positively correlated 
with NKG2D+CD4+ T cell frequencies (R = 0.85 and P < 
0.0001 for IL-10; R = 0.68 and P = 0.0003 for FasL), and 
thus inversely correlated with SLEDAI scores in all of the 27 
matched sample pairs tested (Fig. 8 D). These results suggest 
that the NKG2D+CD4+ T cells are a prominent source of 
immunosuppressive activity in the patient cohort in this study. 
This evidence contrasts results from earlier studies that identi-
fied monocytes, macrophages, and B cells as the main produc-
ers of IL-10, and noted positive correlations between disease 
activity and serum concentrations of IL-10 (32, 33). Possible 
reasons underlying these discrepancies are unknown.
Expression of NKG2D ligands in juvenile-onset SLE
In cancer patients, population expansions of the NKG2D+ 
CD4+ T cells are dependent on the presence of tumor-associ-
ated MICA and correlate with serum concentrations of sMICA 
(17). Because of lack of access to tissue biopsies, we were un-
able to explore disease-associated NKG2D ligand expression 
in juvenile-onset SLE. However, we detected sMICA in all 
of the 72 patient plasma samples tested, but in none of 20 
age-matched controls. Although an inverse trend relationship 
between sMICA and SLEDAI scores was apparent, plotting 
sMICA concentrations against NKG2D+CD4+ T cell fre-
quencies revealed no correlation among the available 27 
matched sample pairs (Fig. 6 E and not depicted). This dis-
parity could be caused by the presence of anti-MICA auto-
antibodies, which have been found in cancer patients with 
anti-CTLA-4 therapy-induced autoimmunity and may ob-
scure ELISA detection of sMICA (34). In fact, using a micro-
bead-based screening assay, we detected anti-MICA antibodies 
in all of the 27 SLE patient plasma samples whereas all of 20 
cancer patient samples containing sMICA were negative (un-
published data). In addition or alternatively to MICA, other 
NKG2D ligands such as its close relative MICB, or ULBP2 
and ULBP3, which are normally expressed on B cells, could 
provide for NKG2D+CD4+ T cell costimulation in juvenile-
onset SLE (Fig. 1 A).
DISCUSSION
The  normal  peripheral  CD4  T  lymphocyte  compartment 
harbors small numbers of T cells with activation-independent, 
Figure 5.  IL-10, TGF-, IFN-, and FasL production by normal 
peripheral blood-derived NKG2D+CD4+ T cell clones. (A) Detection of 
intracellular IL-10 and surface LAP-TGF-1, and of IL-10 and IFN- among 
clones established under nonpolarizing conditions from sorted naive (24 T 
cell clones) and central and effector (CM and EM) memory (30 T cell 
clones) and effector (CM) memory (20 T cell clones) NKG2D+CD4+ T cells, 
respectively. Dots in scatter plots represent the percentage of positive  
cells among a given T cell clone. Clones were derived from three donors. 
(B) ELISA for FasL in supernatants of NKG2D+CD4+ T cell clones (identical 
to those used in Fig. 1) generated by autologous B cell stimulation. Condi-
tions of experimental T cell stimulations are indicated in the bar graph. 
Data in A and B are representative of three separate experiments.JEM VOL. 206, April 13, 2009 
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Previous data obtained with T cell clones from an ovarian 
cancer patient suggested that NKG2D+CD4+ T cells recognize 
normal self-antigens (17). On the other hand, CMV-driven 
expansions  of  NKG2D+CD4+  T  cells  in  CMV-seroposi-
tive individuals pointed toward a role of these T cells in host 
defense  (22).  Our  study  shows  that  normally  occurring 
NKG2D+CD4+ T cells are autoreactive and unresponsive to-
ward classical recall antigens.
Although NKG2D+CD4+ T cells with specificities for 
microbial determinants other than those tested may exist, 
their proportionally large responses to autologous B cells 
constitutive NKG2D expression. Our results establish that 
these T cells constitute a discrete T cell subset characterized 
by autoreactivity, an immunosuppressive IL-10 and TGF- 
cytokine signature, and regulatory effects. We originally de-
tected expansions of these T cells in cancer patients and inferred 
a regulatory role from their ability to cause FasL/Fas-medi-
ated inhibition of bystander T cell proliferation as a result of 
NKG2D costimulation in vitro (17). This idea is supported 
by the inverse correlation between NKG2D+CD4+ T cell 
frequencies and disease activity in juvenile-onset SLE dem-
onstrated in this study.
Figure 6.  Increased proportions of NKG2D+CD4+ T cells and inverse correlation with disease activity in juvenile-onset SLE. (A) Frequencies of 
NKG2D+CD4+ T cells (percentage of CD8CD4+ T cells) in six disease and three age-matched control samples. (B) Overall data point distribution and statis-
tical evaluation (R = 0.5; P = 0.02) of NKG2D+CD4+ T cell frequencies in relationship to SLEDAI scores in the 27 patient samples studied. (C) Comparison 
of mean frequencies (positions indicated by short horizontal bars) of NKG2D+CD4+ T cells in 13 active and 14 inactive juvenile-onset SLE and 14 age-
matched control samples. Individual comparisons are bracketed, and P values are indicated. (D) NKG2D+CD4+ T cell frequencies in five patients at times of 
flare or remission of disease. Numbers refer to SLE subjects listed in Table I. (E) Plotting of sMICA concentrations in 72 juvenile-onset SLE plasma samples 
against SLEDAI scores (R = 0.27; P = 0.01). All data shown in A–E were derived from single analyses of patient and control samples.800 IMMUNOSUPPRESSIVE NKG2D+CD4+ T CELLS | Dai et al.
because of limited antigen expression and/or specific condi-
tions in tissue microenvironments or that these T cells are not 
truly naive despite a phenotype conventionally associated 
with that stage. It may be somewhat puzzling that only B cells 
among PBMCs stimulated NKG2D+CD4+ T cell in vitro 
proliferation, an observation that cannot be analytically ad-
dressed without knowledge of T cell antigens, their expres-
sion, and processing.
Previously, immunosuppressive and proinflammatory 
and cytolytic functions have been associated with CD4 T 
cells that express NKG2D (11, 17, 18). We addressed this 
heterogeneity  by  examining  the  functional  signature  of 
NKG2D+CD4 T cells from normal peripheral blood. The 
results indicate that this T cell population is homogeneously 
immunosuppressive and lacks a proinflammatory profile and 
cytolytic capacity. Although some of the NKG2D+CD4 T 
cells produce IFN-, these responses are minimal. Normal 
imply that autoreactivity is a predominant if not all-inclusive 
characteristic. Moreover, NKG2D+CD4+ T cells that recog-
nize recall antigens are set apart from the autoreactive subset 
because they coexpress CD8, and thus correspond to dou-
ble-positive CD8+CD4+ effector T cells that are known to be 
enriched for microbial specificities (25). The identity and ex-
pression of the self-antigens recognized by the autoreactive 
NKG2D+CD4+ T cells remain unknown, although their ex-
pression in peripheral blood B cells and diverse cancer cells 
may suggest a ubiquitous tissue distribution and ample op-
portunity for T cell priming. Under this assumption, the pre-
dominantly naive phenotype of the NKG2D+CD4+ T cells 
in normal individuals seems unusual, but is not without prec-
edent as, for example, normal donor-derived CD8 T cells 
specific for the broadly expressed melanocyte Melan-A/
MART-1 antigen are mostly naive as well (35). On the other 
hand, it is possible that NKG2D+CD4+ T cell priming is rare 
Table I.  SLE patient characteristics
Subject Gender Age at onset Age at draw SLEDAI Prednisonea Other immunomodulatory 
medicationsa
NKG2D+CD4+ T 
cellsb
yr yr mg/kg/day %
1 F 13.1 13.8 4 0.30 HCQ, MTX 11.6
15.4 4 0.13 AZT 15.3
2 F 11.8 16.1 2 0.14 HCQ 27.0
17.3 12 0.00 2.0
3 F 11.9 12.5 12 0.35 HCQ 7.0
14.5 0 0.50 HCQ, dapsone 12.7
4 F 14.9 16.5 0 0.08 HCQc 25.8
17.3 2 0.28 HCQc 15.6
5 F 10.0 10.2 10 0.00 HCQ 5.0
11.6 4 0.00 HCQ 39.0
12.1 5 0.00 HCQ 18.5
6 M 16.6 17.3 27 0.50 4.78
18.3 4 0.04 HCQ, Cycc 16.6
7 M 15.0 15.3 11 0.00 Dicloxacillin 8.08
16.1 2 0.36 HCQ, MMF 17.53
8 F 7.0 12.2 4 0.00 HCQ 11.8
9 M 13.9 14.2 2 1.25 HCQ 18.0
10d M 7.1 11.0 2 0.14 HCQ, dapsone 32.0
11 F 8.9 18.2 4 0.00 HCQ 28.7
12 F 9.2 17.8 8 0.00 HCQ, sulfasalazine 8.07
13 F 12.2 15.7 8 0.00 HCQ, MTX 4.0
14 F 7.1 8.1 19 0.37 HCQ, MMF 17.0
15 F 8.1 9.2 4 0.00 19.92
16 F 18.0 18.9 8 1.27 5.6
17 F 11.6 11.9 6 0.00 HCQ 14.0
18 F 9.4 9.9 6 0.00 5.8
19 F 14.0 15.5 8 0.13 HCQ, MMF 7.02
aTherapeutic regimens including prednisone ≥0.2 mg/kg/day and/or azathioprine (AZT), dapsone, mycophenolate mofetil (MMF), methotrexate (MTX), or sulfasalazine were 
considered immunosuppressive.
bPercentage of CD8CD4+ T cells.
cPatients enrolled in a placebo-controlled atorvastatin trial.
dPatient with C1q deficiency.
Cyc, cyclophosphamide; HCQ, hydroxychloroquine.JEM VOL. 206, April 13, 2009 
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NKG2D+CD4+ T cells appear to be associated with regula-
tory effects. Direct evidence for a role in attenuating disease 
activity cannot be readily obtained because equivalent T cells 
have not been observed in mice. It also remains unknown 
which NKG2D+CD4+ T cell functions, alone or combined, 
may affect disease activity. However, FasL-dependent effects 
are most likely relevant because Fas expression is unusually 
abundant among lupus patient T and B cells (38, 39). At least 
in vitro, lupus T cells are susceptible to NKG2D+CD4+ T 
cell–derived FasL-dependent growth arrest, and prelimi-
nary data suggest similar effects on patient B cells as well 
peripheral blood NKG2D+CD4+ T cells are thus clearly dis-
tinct from the proinflammatory and cytolytic CD28CD4+ 
T cells with cytokine-induced NKG2D expression in pe-
ripheral blood and synovia of RA patients, and from lamina 
propria NKG2D+CD4+ T cells in Crohn’s disease, which are 
positive for perforin (11, 18).
The association of the immediate, quasi–effector-like IL-10 
response with a naive NKG2D+CD4+ T cell phenotype is 
highly unusual. At least we are not aware of precedent for a 
similar uncoupling of functional differentiation from T cell 
maturation. Our results thus invoke an unconventional, possi-
bly antigen-independent, mechanism for IL-10 imprinting of 
these T cells, which may involve epigenetic derepression of 
IL-10 loci early in T cell ontogeny, perhaps together with con-
stitutive expression of transcription factors (36, 37). Alterna-
tively, as discussed earlier, these T cells may not be truly naive. 
It is unclear whether NKG2D+CD4+ T cells are irreversibly 
IL-10 committed. However, these T cells retain some cytokine 
flexibility as they acquire the ability to produce TGF- and 
IFN- with functional maturation. In regard to the IL-10/
TGF- profile, the NKG2D+CD4+ T cells superficially re-
semble naturally occurring and inducible T reg cells. However, 
as we have previously reported, they are clearly distinct (17).
Based on their in vitro functional attributes and inverse 
correlation with disease severity in juvenile-onset SLE, the 
Figure 7.  Autoreactivity and cytokine signature of NKG2D+CD4+ T cells in juvenile-onset SLE. (A) Left histogram shows CFSE dilution of sorted 
patient-derived NKG2D+CD4+ T cells in response to stimulation by autologous (open profile), but not allogeneic B cells (shaded profile). Data shown are 
representative of results obtained from single analyses of two samples each from patients with active or inactive disease. Middle and right histograms 
show stainings for intracellular IL-10 and surface LAP-TGF-1 of patient NKG2D+CD4+ T cells stimulated with PMA and ionomycin. Data shown are repre-
sentative of results obtained with 13 active and 14 inactive disease samples analyzed once. (B) Minimal staining for intracellular IFN-, and absence of 
staining for TNF- and IL-17 among effector memory (EM) and total patient NKG2D+CD4+ T cell populations, respectively. Data shown are representative 
of results obtained with 13 active and 14 inactive disease samples analyzed once. All histograms displaying intracellular cytokine stainings were gener-
ated based on the gating tree shown in Fig. 4 A. Numbers above horizontal bars in histograms indicate the percentage of positive cells. Histograms shown 
in black and gray are from stimulated and unstimulated T cells, respectively.
Table II.  NKG2D+CD4+ T cell subset segregation in juvenile-
onset SLE and controls
NKG2D+CD4+ T cells  Active disease Inactive disease Controls
n = 13 n = 14 n = 14
Naïve 
(CD45ROCCR7+)
5.3% (±2.8)a 6.1% (±4) 73.5% (±9)
Central memory 
(CD45ROCCR7+)
45.8% (±13.4) 47.1% (±14.3) 17.9% (±8.1)
Effector memory 
(CD45RO+CCR7)
46.9% (±14.2) 48.9% (±13.7) 8.7% (±5.6)
aMean (in percent) ± SD of NKG2D+CD4+ T cells positive for the indicated phenotype 
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(unpublished data). An immunosuppressive role for NKG2D+ 
CD4+ T cell–derived IL-10 in lupus patients may be contro-
versial because IL-10 is thought to promote disease (32, 33, 
40). TGF-, on the other hand, is generally considered anti-
inflammatory, although its pleiotropic effects include a role 
in the differentiation of inflammatory Th17 cells and tissue 
damage (41).
In cancer patients, expansions of the NKG2D+CD4+ T 
cells are dependent on tumor expression of MICA, and their 
frequencies are correlated with serum concentrations of 
sMICA providing for NKG2D costimulation of T cell prolif-
eration (17). Although sMICA was present in all juvenile-
onset SLE patients studied, its tissue source could not be 
determined.  It  is  thus  unclear  which  tissue  environments 
combine MHC class II self-antigen presentation and NKG2D 
ligand expression. Other conditions conducive for stimula-
tion of NKG2D+CD4+ T cell expansions and functions likely 
include the unmasking of their autoreactivity by breakdown 
of peripheral tolerance. As suggested by our results and other 
studies of autoreactive T cells (23, 42), loss of CD25+ T reg 
cell  functions  may  be  one  requirement—a  condition  that 
may be met by T reg cell impairments in SLE (30). Gradually 
expanding NKG2D+CD4+ T cell populations may thus, in 
some ways, compensate for T reg cell deficiencies. This is 
supported  by  our  confirmation  of  NKG2D+CD4+  T  cell 
functional competence in juvenile-onset SLE. However, this 
observation raises the question of how these T cells can   
remain uncompromised by the multitude of lymphocyte   
functional abnormalities that include TCR “rewiring” and 
signaling and gene regulation defects in this disease (31).
As with other autoimmune diseases, there is considerable 
interest in restoring immune tolerance by reconstitution of 
functionally active T reg cells in SLE (43). However, adoptive 
transfer approaches are hampered by difficulties, including the 
absence of surface markers for unequivocal identification and 
the  isolation  of  conventional  T  reg  cells.  In  contrast,  the 
NKG2D+CD4+ T cells can be readily identified and in vitro 
expanded, and may thus offer new treatment modalities.
MATERIALS AND METHODS
Subjects and blood samples. Normal peripheral blood samples were ob-
tained from healthy adult volunteers who consented in accordance with a 
protocol approved by the Internal Review Board (IRB) at Fred Hutchinson 
Figure 8.  Functional competence of NKG2D+CD4+ T cells in juve-
nile-onset SLE. (A) IL-10, TGF-, and FasL in supernatants of 
NKG2D+CD4+ T cells from active and inactive disease patients and age-
matched controls. Sorted T cells were stimulated as indicated, and media-
tors were determined by ELISA. Data shown represent means of values 
obtained with each of five active and inactive SLE patient and control 
samples that were analyzed once. Error bars indicate SDs. (B and C) CFSE 
dilution histograms of gated NKG2DCD4+ T cells (B, normal donor T cell 
line; C, ex vivo–sorted patient T cells) co-cultured with purified patient or 
control NKG2D+CD4+ T cells activated with solid-phase anti-CD3 alone 
and exposed to sMICA alone or together with the antagonist anti-Fas. 
Data shown are representative of each of five active and inactive SLE 
patient and control samples analyzed once. (D) Plotting of IL-10 and FasL 
plasma concentrations against NKG2D+CD4+ T cell frequencies (R = 0.85, 
P < 0.0001; and R = 0.68, P = 0.0003) from 27 juvenile-onset SLE patient 
samples analyzed once.
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per U-bottom well) were cultured with PHA (1 µg/ml, positive control) or 
irradiated autologous PBMC stimulator populations, with or without addi-
tional lymphocyte depletions as indicated in Fig. 1, at a responder-to-stimu-
lator cell ratio of 1:1. Purified B cell stimulators were used at a ratio of 1 per 
10 T cells. The anti–MHC class II, -ULBP2, and -ULBP3 blocking mAbs, 
all used at 10 µg/ml, were TU39 (BD) and 6F6 and 4F9 (our reagents), re-
spectively. Cells were harvested after 4–5 d of culture and analyzed for 
NKG2D and CD4 expression and CFSE dilution by multicolor flow cytom-
etry. T cell clones established in the presence of autologous B cells were 
tested for [3H]thymidine incorporation after exposure to irradiated autolo-
gous or allogeneic B cells in the presence or absence of mAb TU39 (10 µg/ml) 
or L243 (anti-HLA-DR; 5 µg/ml; American Type Culture Collection). For 
recall response assays, monocytes (5 × 104 cells/U-bottom well) were   
cultured with purified CFSE-labeled NKG2D+CD4+ or NKG2DCD4+ 
memory T cells at a ratio of 1:1 in the presence of recombinant CMV pp65 
(2 µl/ml; Miltenyi Biotech), tetanus toxoid (1 µg/ml; Calbiochem), PPD 
from M. tuberculosis (5 µg/ml; Statens Serum Institute), and heat-inactivated 
C. albicans (10 µg/ml; Greer Laboratories), added individually or as a cocktail 
as indicated in Fig. 3. CFSE dilution of NKG2D+ and NKG2DCD4+ T 
cells and coexpression of CD8 and CD8 were evaluated by multicolor 
flow cytometry using anti-CD3–Alexa Fluor 700, anti-CD8–PerCPCy5.5, 
anti-CD8–PE (clone 2ST8.5H7; BD), anti-CD4–APC–Alexa 750 (clone 
S3.2; Invitrogen), and anti-NKG2D–APC after 6–10 d of culture. T cell 
stimulations (106 cells/ml) for cytokine profiling and CD107a mobilization 
assays were with PMA (50 ng/ml; Sigma-Aldrich) and ionomycin (0.5 µg/ml; 
Sigma-Aldrich) at 37°C. Stimulation times were optimized for each cyto-
kine and CD107a. Monensin (0.7 µg/ml; BD) and/or brefeldin A (10 µg/
ml; Sigma-Aldrich) were present throughout the final 4 h of stimulation. For 
ELISA for cytokines and FasL, T cells (5 × 104 per flat-bottom well) were 
plated onto solid-phase anti-CD3 (OKT3; Ortho Biotech) alone or together 
with anti-NKG2D (mAb 1D11) or endotoxin-free recombinant sMICA 
(20 ng/ml) (49), or stimulated with irradiated autologous B cells in the pres-
ence or absence of anti-HLA-DR (mAb L243) (17). IL-10, TGF-1, and 
FasL were quantified in 24-h culture supernatants by commercial ELISA 
(R&D Systems). Redirected lysis assays using anti-CD3 and mouse mastocy-
toma P815 cells, and the assay for FasL-mediated inhibition of proliferation 
of NKG2DCD4+ T cells by NKG2D+CD4+ T cells have been previously 
described (6, 17). IL-15–mediated NKG2D induction in NKG2DCD4+ T 
cells was as described and was monitored by flow cytometry (11). Co-culture 
experiments assessing FasL-mediated regulatory functions of NKG2D+CD4+ 
T cells were as previously described (17). In brief, sorted patient- or control 
donor–derived  NKG2D+CD4+  T  cells  were  mixed  with  CFSE-labeled 
NKG2DCD4+ responder T cells (normal donor-derived T cell lines or ex 
vivo–sorted active and inactive SLE patient T cells) and activated with solid-
phase anti-CD3 alone or together with sMICA in the presence or absence of 
antagonist anti-Fas (17).
Polychromatic  flow  cytometry.  Functional  profiling  in  conjunction 
with maturational phenotypes was done by surface and intracellular staining 
of unstimulated (to assess presence of perforin and granzymes A and B) or 
short-term stimulated (to assess surface mobilization of CD107a and cyto-
kine production) PBMCs and CBMCs. Cell viability was assessed using a 
LIVE/DEAD Fixable Violet Dead Cell Stain kit (Invitrogen). For surface 
staining, cells were incubated in PBS/10% human serum/0.15 sodium azide 
for 15 min at room temperature, exposed to pretitrated mAb cocktails for 
20 min at 4°C, and washed in PBS/1% BSA/0.15 sodium azide. For intra-
cellular stainings, cells were permeabilized, stained for cytotoxic proteins or 
intracellular cytokines, and washed using Cytofix/Cytoperm kit reagents 
(BD). Unless otherwise specified, all mAbs were purchased from BD. QDot 
and Alexa Fluor 680 (Zenon Alexa 680 Mouse IgG1 Labeling kit; Invitro-
gen) conjugates were made in-house. The surface marker antibody cocktail 
included anti-CD3–Alexa Fluor 700, anti-CD4–APC–Alexa 750 (clone S3.2; 
Invitrogen), anti-CD8–PerCPCy5.5, anti NKG2D–APC, anti-CD45RO–
ECD, and anti-CCR7–PECy7 (clone 3D12). More extensive maturation 
phenotyping used anti-CD3–QDot 565, anti-CD4–APC–Alexa Fluor 750, 
Cancer Research Center. Blood samples for assessment of recall responses 
were from CMV-seropositive and tuberculin skin test–positive donors. Um-
bilical cord blood from normal deliveries was collected according to IRB 
guidelines. 19 patients diagnosed before (n = 18) or at age 18 (n = 1) who 
fulfilled the American College of Rheumatology criteria for the classification 
of SLE and age-matched healthy volunteers were recruited and consented 
under a research protocol approved by the IRB of the Children’s Hospital   
and Regional Medical Center, Seattle. Peripheral blood and clinical and   
laboratory data were collected for each individual, and disease activity was 
determined according to the modified SLEDAI 2000 (29). Demographic 
characteristics, disease activity status, and immunomodulatory medications of   
all subjects are listed in Table I. Disease activity scores of five or greater were 
considered to represent active disease or “flare”; scores of less than five   
were indicative of inactive disease or “remission” (44, 45). All blood samples 
were processed within 6 h of collection (46). PBMCs and cord blood mono-
nuclear cells (CBMCs) were isolated by density centrifugation over Ficoll-
Hypaque and cryopreserved or directly analyzed. Patient and age-matched 
control plasma was collected before PBMC isolation and cryopreserved.   
27 PBMCs and matched plasma samples were collected from 19 SLE patients. 
Serial samples obtained at times of high or low disease activity were available 
from six patients. Additional plasma or serum samples were available from 44 
juvenile-onset SLE patients and 20 tumor patients positive for sMICA (17).
Lymphocyte subset purifications, T cell cloning, and CFSE label-
ing. All cell purifications involved FACSAria sorting (BD) and/or micro-
bead-facilitated (MACS methodology; Miltenyi Biotech) cell selection, and 
yielded >99% pure cell populations. Unless otherwise indicated, all mAbs 
were obtained from BD. Antibody coupling to quantum dots (Quantum 
Dot Corporation) was according to protocol (http://drmr.com/abcon/ 
index.html).
NKG2D+CD8CD4+  T  cells  and  control  NKG2DCD8CD4+  T 
cells were sorted from negatively bead-enriched (CD4+ T Cell Isolation 
kit II) CD4 T cells using the following mAb cocktail: anti-CD3–Alexa 
Fluor 700 (clone UCHT1), anti-CD8–PerCPCy5.5 (clone SK1), anti-
CD4–FITC  (clone  RPA-T4),  and  anti-NKG2D–APC  (clone  1D11;  6).   
Naive and memory subsets of NKG2D+CD8CD4+ T cells were sorted   
as CD45ROCD62L+CD28+CD27+ (naive) and CD45RO+CD62L+/ 
(memory) or CD45RO+CD62L (effector memory) T cells by adding anti-
CD45RO–ECD (PE–TR; clone UCHL1; Beckman Coulter), anti-CD62L–
PE (clone SK11), anti-CD28–PECy5 (clone CD28.2), and anti-CD27–QDot 
605 (clone M-T271) to the antibody cocktail. For select recall response as-
says, double-positive CD4+CD8+ NKG2D+ T cells were copurified together 
with NKG2D+CD8CD4+ T cells. NKG2D memory CD4 T cells were 
sorted from negatively bead-selected memory CD4 T cells (Memory CD4+ 
T Cell Isolation kit) using anti-NKG2D–PE. Depletion of T cells, CD25+ 
lymphocytes, B cells, or monocytes from autologous stimulator PBMCs used 
CD3 MicroBeads, CD25 MicroBeads II, CD19 MicroBeads, and CD14 Micro-
Beads, respectively. CD19+ B cells (B Cell Isolation kit II) and CD14+ 
monocytes (Monocyte Isolation kit II) were purified from PBMCs by nega-
tive selection. Antigen-specific T cell clones were generated from single-cell 
sorted CD3+CD4+CD8NKG2D+ or CD3+CD4+CD8CD45ROCD62
L+CD28+CD27+NKG2D+ cells exposed to two rounds of weekly stimula-
tion with irradiated (40 Gy) autologous CD19+ B cells in the presence of IL-
2 (% IU/ml) and IL-7 (10 ng/ml), as previously described (47). To determine 
NKG2D+CD4+ T cell cytokine signatures, naive and memory subset-de-
rived clones were established from single cells in the presence of 105 irradi-
ated allogeneic PBMC feeders and 1 µg/ml PHA in nonpolarizing conditions 
(10 ng/ml TGF-, 1 µg/ml anti–IL-4, and 2 µg/ml anti–IL-12; all from 
R&D Systems) (48); juvenile-onset SLE patient– and normal donor–derived 
NKG2DCD4+ T cell lines were established as previously described (17).
T cell stimulations, proliferation and cytotoxicity assays, and ELISA 
of soluble mediators. All T cell stimulations were in AIM V serum-free 
medium (Invitrogen). To test for autoreactivity, CFSE-labeled purified 
NKG2D+CD4+ and control NKG2DCD4+ responder T cells (5 × 104 cells 804 IMMUNOSUPPRESSIVE NKG2D+CD4+ T CELLS | Dai et al.
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